Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | PPID | Q08752 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921603 | 0.85 | NPSR1 (0.39) | SMN1; SMN2L3MBTL1GSTO1NPSR1MEN1 | |
| SCHEMBL2928884 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2NFKB1NFKB2RELANPSR1 | |
| SCHEMBL13248101 | 0.77 | NFKB1 (0.37) | SMN1; SMN2L3MBTL1CYP4F2CYP4A11NFKB1 | |
| SCHEMBL29265680 | 0.77 | P2RX3 (0.37) | SMN1; SMN2L3MBTL1CYP4F2CYP4A11NFKB1 | |
| SCHEMBL3058381 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL31439848 | 0.76 | ADRA2C (0.40) | SMN1; SMN2L3MBTL1NPSR1MEN1NPC1 | |
| SCHEMBL4837483 | 0.76 | KDM4E (0.50) | SMN1; SMN2L3MBTL1NPSR1MEN1HTT | |
| SCHEMBL4840210 | 0.75 | POLB (0.46) | SMN1; SMN2MEN1KMT2AGAAPOLB | |
| SCHEMBL31439932 | 0.75 | PDK2 (0.38) | SMN1; SMN2L3MBTL1NPSR1MEN1NPC1 | |
| SCHEMBL14587288 | 0.75 | NPSR1 (0.37) | SMN1; SMN2L3MBTL1GSTO1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
| EP-2225253-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009069100-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | SMN1; SMN2 3459/4885L3MBTL1 4239/4885CYP4F2 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.